GUARDANT HEALTH CL. A

Guardant Health reported a record quarter with revenue up 44% to $335 million and raised its full-year guidance to $1.34–$1.36 billion. Growth was driven by core oncology revenues and the expanding Shield colorectal screening program, while a new lab process is expected to cut the cost per Shield test by about 15% by year-end. The company aims for cash-flow breakeven by the end of 2027; in the near term it remains loss-making with an expected cash burn of roughly $200 million in 2026. Chart‑wise, the stock broke out of a sideways consolidation and is trading just below its previous all-time high. » Más en finanzen.net

Guardant Health said at the Morgan Stanley conference it posted more than 40% revenue growth in Q2, an oncology volume increase of over 60% and Shield growth of more than 250%. According to management, Shield covers 80% of eligible individuals (about 94 million people) and cost per test is expected to fall from just over $400 to roughly $350 by year-end, with a long-term target of $200. Guardant360 Liquid CDx received an expanded FDA approval as the sole companion diagnostic for Camizestrant; the company expects ADLT status for Guardant360 in H1 2025 and sees further growth potential from combined screening, profiling and MRD applications despite near-term pricing and reimbursement pressure. » Más en de.investing.com

Guardant Health announced that EviCore by Evernorth has added the Shield blood test for colorectal cancer early detection to its clinical guidelines effective January 1, 2027. Reimbursement will apply to insured individuals aged 45 and older at average risk, expanding the covered population to about 94 million people across 23 states. Shield is FDA-cleared for primary screening using methylation partitioning cell-free DNA technology; a positive result requires follow-up colonoscopy. The test is included in American Cancer Society and National Comprehensive Cancer Network guidelines and has already been used more than 200,000 times. » Más en de.investing.com